The emerging role of microRNAs in resistance to lung cancer treatments

Cancer Treatment Reviews

Volumn 41, Issue 2, 2015, Pages 160-169

  MacDonagh, Lauren ^a   Gray, Steven G ^a   Finn, Stephen P ^a   Cuffe, Sinead ^a   O'Byrne, Kenneth J ^a,b   Barr, Martin P ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Cancer therapies; Chemotherapy; Lung cancer; MicroRNA; Resistance

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MICRORNA; PLATINUM DERIVATIVE; SMALL UNTRANSLATED RNA; TAXANE DERIVATIVE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC ANTIMETABOLITE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; TAXOID; TNFSF10 PROTEIN, HUMAN;

APOPTOSIS; BIOGENESIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; DRUG EFFICACY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; LUNG CANCER; PERSONALIZED MEDICINE; RADIOSENSITIVITY; REVIEW; ADJUVANT THERAPY; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; METABOLISM; MORTALITY; RADIATION DOSE;

ANGIOGENESIS INHIBITORS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICRORNAS; PLATINUM COMPOUNDS; RADIATION TOLERANCE; RADIOTHERAPY, ADJUVANT; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAXOIDS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84921752663     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.12.009     Document Type: Review

References (121)

1. Jemal A., et al. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Sarkar F.H., et al. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat 2010, 13(3):57-66.
3. Allen K.E., Weiss G.J. Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol Cancer Ther 2010, 9(12):3126-3136.
4. Wang Z., et al. Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist Updat 2010, 13(4-5):109-118.
5. Szakacs G., et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discovery 2006, 5(3):219-234.
6. Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6(4):259-269.
7. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009, 10(10):704-714.
8. Kim V.N. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005, 6(5):376-385.
9. Lee Y., et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004, 23(20):4051-4060.
10. Cai X., Hagedorn C.H., Cullen B.R. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 2004, 10(12):1957-1966.
11. Lee Y., et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003, 425(6956):415-419.
12. Han J., et al. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev 2004, 18(24):3016-3027.
13. Yi R., et al. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 2003, 17(24):3011-3016.
14. Winter J., et al. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009, 11(3):228-234.
15. Lund E., et al. Nuclear export of microRNA precursors. Science 2004, 303(5654):95-98.
16. Gregory R.I., et al. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 2005, 123(4):631-640.
17. Lee Y., et al. The role of PACT in the RNA silencing pathway. EMBO J 2006, 25(3):522-532.
18. MacRae I.J., et al. In vitro reconstitution of the human RISC-loading complex. Proc Natl Acad Sci USA 2008, 105(2):512-517.
19. Dalmay T., Edwards D.R. MicroRNAs and the hallmarks of cancer. Oncogene 2006, 25(46):6170-6175.
20. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
21. Lima R.T., et al. MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer 2011, 47(2):163-174.
22. Karube Y., et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci 2005, 96(2):111-115.
23. Kumar M.S., et al. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007, 39(5):673-677.
24. Takamizawa J., et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004, 64(11):3753-3756.
25. Johnson S.M., et al. RAS is regulated by the let-7 microRNA family. Cell 2005, 120(5):635-647.
26. Kumar M.S., et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA 2008, 105(10):3903-3908.
27. Esquela-Kerscher A., et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 2008, 7(6):759-764.
28. Johnson C.D., et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007, 67(16):7713-7722.
29. He L., et al. A microRNA polycistron as a potential human oncogene. Nature 2005, 435(7043):828-833.
30. Hayashita Y., et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005, 65(21):9628-9632.
31. Matsubara H., et al. Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92. Oncogene 2007, 26(41):6099-6105.
32. Hu Z., et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010, 28(10):1721-1726.
33. Yu S.L., et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008, 13(1):48-57.
34. Yu L., et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer 2010, 127(12):2870-2878.
35. Landi M.T., et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 2010, 16(2):430-441.
36. Yanaihara N., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9(3):189-198.
37. Garofalo M., et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 2012, 18(1):74-82.
38. Garofalo M., et al. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 2008, 27(27):3845-3855.
39. Giovannetti E., et al. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol 2012, 81(2):103-122.
40. Chen X., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18(10):997-1006.
41. Li Y., et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009, 69(16):6704-6712.
42. Melkamu T., et al. Alteration of microRNA expression in vinyl carbamate-induced mouse lung tumors and modulation by the chemopreventive agent indole-3-carbinol. Carcinogenesis 2010, 31(2):252-258.
43. Seike M., et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci USA 2009, 106(29):12085-12090.
44. Burchenal J.H., Robinson E., et al. The induction of resistance to 4-amino-N10-methylpteroylglutamic acid in a strain of transmitted mouse leukemia. Science 1950, 111(2875):116.
45. Climent J., et al. Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. Cancer Res 2007, 67(2):818-826.
46. Blower P.E., et al. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther 2007, 6(5):1483-1491.
47. Yang M., et al. High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur J Cancer 2012.
48. Capodanno A., et al. Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features. Int J Oncol 2013, 43(3):765-774.
49. Wang Y., et al. The prognostic value of miR-21 and miR-155 in non-small-cell lung cancer: a meta-analysis. Jpn J Clin Oncol 2013, 43(8):813-820.
50. Hwang J.H., et al. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS ONE 2010, 5(5):e10630.
51. Pan X., Wang Z.X., Wang R. MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol Ther 2011, 10(12):1224-1232.
52. Zhang J.G., et al. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta 2010, 411(11-12):846-852.
53. Shi L., et al. MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res 2010, 1352:255-264.
54. Wang W., et al. MiR-21 inhibitor sensitizes human OSCC cells to cisplatin. Mol Biol Rep 2012, 39(5):5481-5485.
55. Chen Y., et al. Micro-RNA-21 regulates the sensitivity to cisplatin in human neuroblastoma cells. J Pediatr Surg 2012, 47(10):1797-1805.
56. Liu Z.L., et al. MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol Cell Biochem 2013, 372(1-2):35-45.
57. Ranade A.R., et al. MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer. J Thorac Oncol 2010, 5(8):1273-1278.
58. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007, 7(8):573-584.
59. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22(47):7265-7279.
60. Zhu W., et al. MiR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 2012, 69(3):723-731.
61. Zhu W., et al. MiR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol 2012, 29(1):384-391.
62. Gao W., et al. MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. Cancer Biol Ther 2012, 13(5):330-340.
63. Zhu W., et al. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010, 127(11):2520-2529.
64. Zang Y.S., et al. MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression. Cancer Gene Ther 2012, 19(11):773-778.
65. Galluzzi L., et al. MiR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010, 70(5):1793-1803.
66. Ceppi P., et al. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 2010, 8(9):1207-1216.
67. Tellez C.S., et al. EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res 2011, 71(8):3087-3097.
68. Pacurari M., et al. The microRNA-200 family targets multiple non-small cell lung cancer prognostic markers in H1299 cells and BEAS-2B cells. Int J Oncol 2013, 43(2):548-560.
69. Zhang X., et al. MiR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1. Lung Cancer 2012, 77(3):488-494.
70. Chen Z., et al. MiRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res 2010, 29:151.
71. Gelfand V.I., Bershadsky A.D. Microtubule dynamics: mechanism, regulation, and function. Annu Rev Cell Biol 1991, 7:93-116.
72. Rui W., et al. Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1). J Cell Mol Med 2010, 14(1-2):206-214.
73. Feng B., et al. MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3. Cancer 2012, 118(13):3365-3376.
74. Feng B., Wang R., Chen L.B. MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett 2012, 317(2):184-191.
75. Du L., et al. MiR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. PLoS ONE 2012, 7(6):e39167.
76. Holleman A., et al. MiR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene 2011, 30(43):4386-4398.
77. Catuogno S., et al. MiR-34c may protect lung cancer cells from paclitaxel-induced apoptosis. Oncogene 2013, 32(3):341-351.
78. Comella P., et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol 2000, 18(7):1451-1457.
79. Xu C., et al. The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci 2007, 120(Pt 17):3045-3052.
80. Chen J.F., et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006, 38(2):228-233.
81. Luo X., et al. Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. J Biol Chem 2008, 283(29):20045-20052.
82. Care A., et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007, 13(5):613-618.
83. Nasser M.W., et al. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem 2008, 283(48):33394-33405.
84. Crawford M., et al. MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. Biochem Biophys Res Commun 2009, 388(3):483-489.
85. Mizutani H., et al. Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sci 2005, 76(13):1439-1453.
86. Donzelli S., et al. MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ 2012, 19(6):1038-1048.
87. Yin E., et al. Gene expression changes in mouse brain after exposure to low-dose ionizing radiation. Int J Radiat Biol 2003, 79(10):759-775.
88. Oh J.S., et al. Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras. Int J Radiat Oncol Biol Phys 2010, 76(1):5-8.
89. Weidhaas J.B., et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007, 67(23):11111-11116.
90. Jeong S.H., Wu H.G., Park W.Y. LIN28B confers radio-resistance through the posttranscriptional control of KRAS. Exp Mol Med 2009, 41(12):912-918.
91. Lee K.M., Choi E.J., Kim I.A. MicroRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. Radiother Oncol 2011, 101(1):171-176.
92. Gao W., et al. MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol 2011, 137(4):557-566.
93. Salim H., et al. MiRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence. Br J Cancer 2012, 107(8):1361-1373.
94. Grosso S., et al. MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death Dis 2013, 4:e544.
95. Huang X., et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 2009, 35(6):856-867.
96. Yang W., et al. Effects of knockdown of miR-210 in combination with ionizing radiation on human hepatoma xenograft in nude mice. Radiat Oncol 2013, 8:102.
97. Lee C.K., et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 2013, 105(9):595-605.
98. Ding L., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455(7216):1069-1075.
99. Paez J.G., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500.
100. Amann J., et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005, 65(1):226-235.
101. Lynch T.J., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139.
102. Pao W., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2(3):e73.
103. Cho W.C., Chow A.S., Au J.S. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur J Cancer 2009, 45(12):2197-2206.
104. Cho W.C., Chow A.S., Au J.S. MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol 2011, 8(1):125-131.
105. Zhong M., et al. MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer. Chem Biol Interact 2010, 184(3):431-438.
106. Chen G., et al. MiR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells. PLoS ONE 2013, 8(3):e60317.
107. Rai K., et al. Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol Cancer Ther 2011, 10(9):1720-1727.
108. Kerbel R.S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. Science 2006, 312(5777):1171-1175.
109. Nieder C., et al. Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev 2006, 32(5):348-364.
110. Sandler A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550.
111. Choi Y.C., et al. Regulation of vascular endothelial growth factor signaling by miR-200b. Mol Cells 2011, 32(1):77-82.
112. Chan Y.C., et al. MiR-200b targets Ets-1 and is down-regulated by hypoxia to induce angiogenic response of endothelial cells. J Biol Chem 2011, 286(3):2047-2056.
113. Zhu X., et al. MiR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. Acta Biochim Biophys Sin 2012, 44(6):519-526.
114. Liu B., et al. MiR-126 restorations down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer 2009, 66(2):169-175.
115. Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett 2012, 320(2):130-137.
116. Zhang L., Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005, 12(3):228-237.
117. Mariani S.M., et al. Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. J Cell Biol 1997, 137(1):221-229.
118. Garofalo M., et al. MiR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009, 16(6):498-509.
119. Acunzo M., et al. MiR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene 2012, 31(5):634-642.
120. Romano G., et al. MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. Proc Natl Acad Sci USA 2012, 109(41):16570-16575.
121. Gottesman M.M. Mechanisms of cancer drug resistance. Annu Rev Med 2002, 53:615-627.